Trial in progress abstracts (TiP)-进行中的试验摘要 Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Congress 2024. It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any pr...
Abstracts accepted for presentation during the ESMO Gynaecological Cancers Congress 2024 Congress will be released online according to a schedule which will be available on the ESMO website in due time. ESMO Merit Travel Grant A restricted number of ESMO Merit Travel Grants to the ESMO Gynaecological...
[7] Breast 2024 - IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC). ...
Trial in progress abstracts (TiP)-进行中的试验摘要 Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Congress 2024. It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any pr...
1.Testing unselected women with newly diagnosed high-grade serous ovarian cancer (HGSOC) for germline pathogenic variants (PVs) in mismatch repair (MMR) genes is unnecessary. European Society for Medical Oncology Congress 2024 abstracts, 779P. ...
Abstracts accepted for presentation during the ESMO Sarcoma and Rare Cancers Congress 2024 will be released online according to a schedule which will be available on the ESMO website in due course. ESMO Merit Travel Grants A limited number of ESMO Merit Travel Grants to the ESMO Sarcoma and Rar...
在2024年ESMO指南中,伊布替尼在所有类型晚期CLL患者一线治疗中均获[I,A]级推荐,且是年轻/Fit患者中唯一获[I,A]级推荐的BTKi,这充分展示了国际权威指南对其的高度认可;同时,I+V等基于伊布替尼的联合方案治疗一线CLL患者的探索也...
Publication schedule of accepted abstracts Abstracts accepted for presentation during the ESMO Breast Cancer 2023 will be released online according to a schedule which will be available on the ESMO website in due course. Presentation of accepted abstracts ...
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/108590-ema-restricts-use-of-prostate-cancer-medicine-xofigo.html Google Scholar 123 J.S. de Bono, S. Oudard, M. Ozguroglu, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate can...
[7] Breast 2024 - IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC). https://cattendee.abstractsonline.com/meeting/20743/presentation/50. ...